Article
Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.
Microbial drug resistance (Larchmont, N.Y.) - 1 Jan 2003
Gillespie Stephen H, Voelker Leroy L, Ambler Jane E, Traini Chris, Dickens Anne
Abstract excerpt
Fluoroquinolones are being increasingly used for acute lower respiratory tract infection where Streptococcus pneumoniae is the most important bacterial pathogen. S. pneumoniae becomes resistant to quinolone antibiotics by mutations in a small section of the parC and gyrA genes. In this study, we...
Topics
- Anti-Infective Agents
- Ciprofloxacin
- DNA Gyrase
- DNA Topoisomerase IV
- Drug Resistance, Microbial
- Fluoroquinolones
- Gemifloxacin
- Microbial Sensitivity Tests
- Mutation
- Naphthyridines
- Streptococcus pneumoniae